Anthony Giovinazzo Receives 2017 Bloom Burton Award
ATLANTA – Troutman Sanders LLP congratulates Anthony Giovinazzo on receiving the 2017 Bloom Burton Award, which honors individuals who have made the greatest impact on Canada’s innovative healthcare industry.
Giovinazzo received the award for his efforts leading Cynapsus Therapeutics Inc., a Canadian pharmaceutical company, in its development of a drug to treat certain symptoms of Parkinson’s disease. The proposed drug, APL-130277, is designed to be a fast acting, easy-to-use, on-demand treatment option for managing OFF episodes. Giovinazzo was selected as the 2017 Bloom Burton Award recipient by a panel of judges that included many international leaders in healthcare investment, entrepreneurship and journalism.
Over the last few years, Troutman Sanders advised Cynapsus with respect to certain intellectual property matters, in its U.S. $72.5 million initial public offering and NASDAQ listing and in its U.S. $624 million all cash sale to Sunovion Pharmaceuticals Inc., a unit of Japan's Dainippon Sumitomo Pharma Co. Ltd.
About Troutman Sanders
With a diverse practice mix, workforce and footprint, Troutman Sanders has cultivated its reputation for a higher commitment to client care for over 120 years. Ideally positioned to help clients across sectors realize their business
goals, the firm’s 650 attorneys transact for growth, resolve mission-threatening disputes and navigate complex legal and regulatory challenges. See
troutman.com for more information.